In this round up we provide you with the biggest headlines and highlights from the IASLC World Conference on Lung Cancer (WCLC) the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
Browsing: Taxonomy > Clinical trials
A Phase III trial involving the combination of immunotherapy and chemotherapy has seen significantly improved overall survival and progression-free survival in extensive-stage small-cell lung cancer patients.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
Scientists have discovered a new computer software system that can be utilized in order to forecast how certain cancers may respond to a new drug even before it has been given to patients.
The prices of cancer drugs have skyrocketed in recent years, with Pharma companies being called out by both patients and Donald Trump. Who is to blame for this increase and how can we make cancer “more affordable”?
A combination of the targeted drug vistusertib with paclitaxel chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
A new study, published in CNS Oncology estimates the survival benefit of adding tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
In this piece, discover key talks and highlights from the World Congress on Gastrointestinal Cancer 2018.
NICE have approved Alecensa for use on the NHS, following positive data from a Phase II trial, including a reduced risk of brain metastasis.